Epidemiological factors associated with ESBL- and non ESBL-producing E. coli causing urinary tract infection in general practice

References

• Hayakawa K, Gattu S, Marchaim D, et al. Epidemiology and Risk Factors for Isolation of Escherichia coli Producing CTX-M-Type Extended-Spectrum β-Lactamase in a Large U.S. Medical Center. Antimicrob Agents Chemother. 2013;57:4010–4018.
   PubMed Web of Science ®Google Scholar
• Peirano G, van der Bij AK, Gregson DB, Pitout JDD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012;50:294–299.
   PubMed Web of Science ®Google Scholar
• Ben-ami R, Arslan H, Pitout JDD, et al. A Multinational Survey of Risk Factors for Infection with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Nonhospitalized Patients. Clin Infect Dis. 2009;49:682–690.
   PubMed Web of Science ®Google Scholar
• Søraaas A, Sundsfjord AS, Sandven I, et al. Risk Factors for Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Enterobacteriaceae–A Case–Control Study in a Low Prevalence Country. PLoS One. 2013;8:1–7.
   Web of Science ®Google Scholar
• Goulenok T, Ferroni A, Bille E, et al. Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect. 2013;84:294–299.
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A, Kiratisin P, Saifon P, et al. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control. 2007;35:606–612.
   PubMed Web of Science ®Google Scholar
• Rogers B, Ingram PR, Runnegar N, et al. Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries. Antimicrob Agents Chemother. 2014;58:2126–2134.
   PubMed Web of Science ®Google Scholar
• Jørgensen SB, Samuelsen O, Sundsfjord A, et al. High prevalence of faecal carriage of ESBL-producing Enterobacteriaceae in Norwegian patients with gastroenteritis. Scand J Infect Dis. 2014;46:462–465.
   PubMed Web of Science ®Google Scholar
• Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56:641–648.
   PubMed Web of Science ®Google Scholar
• Osthoff M, McGuinness SL, Wagen AZ, Eisen DP. Urinary tract infections due to extended-spectrum beta lactamase-producing gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary-referral hospital. Int J Infect Dis. 2015;34:79–83.
   PubMed Web of Science ®Google Scholar
• Foxman B. Extended-spectrum β-lactamase-producing escherichia coli in the united states: time to rethink empirical treatment for suspected E. coli infections? Clin Infect Dis. 2013;56:649–651.
   PubMed Web of Science ®Google Scholar
• Kaye KS, Harris AD, Samore M, Carmeli Y. The Case-Case-Control Study Design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol. 2005;26:346–351.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Struelens M, Amorim J, et al. Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother. 2002;49:289–300.
   PubMed Web of Science ®Google Scholar
• Nyberg SD, Meurman O, Jalava J, Rantakokko-Jalava K. Evaluation of detection of extended-spectrum beta-lactamases among Escherichia coli and Klebsiella spp. isolates by VITEK 2 AST-N029 compared to the agar dilution and disk diffusion methods. Scand J Infect Dis. 2008;40:355–362.
   PubMed Web of Science ®Google Scholar
• Hansen F, Olsen SS, Heltberg O, et al. Characterization of third-generation cephalosporin-resistant escherichia coli from bloodstream infections in Denmark. Microb Drug Resist. 2014;20:316–324.
   PubMed Web of Science ®Google Scholar
• Hsieh C, Shen Y, Hwang K. Clinical implications, risk factors and mortality following community–onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing escherichia coli. J Microbiol Immunol Infect. 2010;43:240–248.
   PubMedGoogle Scholar
• Harris AD, Samore MH, Carmeli Y. Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med. 2000;133:158.
   Google Scholar
• Inns T, Millership S, Teare L, et al. Service evaluation of selected risk factors for extended-spectrum beta-lactamase Escherichia coli urinary tract infections: a case-control study. J Hosp Infect. 2014;88:116–119.
   PubMed Web of Science ®Google Scholar
• Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother. 2014;69:769–772.
   PubMed Web of Science ®Google Scholar
• Sullivan A, Edlund C, Svenungsson B, et al. Effect of perorally administered pivmecillinam on the normal oropharyngeal, intestinal and skin microflora. J Chemother. 2001;13:299–308.
   PubMed Web of Science ®Google Scholar
• Wener KM, Schechner V, Gold HS, et al. Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010;54:2010–2016.
   PubMed Web of Science ®Google Scholar